e.l.f. Beauty Tumbles 38% in 2025: How to Play the Stock for 2026?

e.l.f. Beauty shares have plunged 37.9% YTD after Q2 fiscal 2026 organic sales turned negative amid retailer delays on a price increase and weaker international momentum, while tariff-driven cost inflation (about 75% production in China) has materially compressed gross margins and is expected to persist into fiscal 2026. Rising marketing and SG&A (team expansion, ERP transition, international build-out), plus elevated leverage from the Rhode acquisition, have weighed on adjusted EBITDA and cash flow, prompting sharp analyst downgrades to FY26–27 EPS. Although the brand shows continued consumption strength and Rhode has aided portfolio diversification (notably at Sephora and e‑commerce), the forward P/E of ~22x and a Value Score of F do not yet compensate for the earnings risk; Zacks assigns a #5 (Strong Sell) and recommends caution or reduced exposure until margin stabilization and core growth recovery are evident.

Analysis

e.l.f. Beauty shares have fallen 37.9% year-to-date after fiscal 2026 Q2 organic sales turned negative when several retailers delayed adoption of the company’s August price increase, and international growth weakened on tough comps in Europe. Roughly 75% of production remains in China, and sharply higher tariff rates have materially compressed gross margins; management says tariff headwinds will persist into fiscal 2026 and pricing has not fully offset the cost impact.

Operating leverage is under pressure as marketing spend ramps in the back half of the year and SG&A remains elevated from team expansion, an ERP transition and international build-out; adjusted EBITDA declined year-over-year. The Rhode acquisition increased leverage and raises financial risk while cash-flow conversion is expected to be softer, prompting sharp downward revisions to fiscal 2026–27 EPS and a Zacks Rank #5 (Strong Sell).

Valuation has fallen to a forward P/E of ~22.3x versus an industry ~29.2x and a Value Score of F, but the brand retains strengths: market-leading consumption growth, share gains and the Rhode debut at Sephora and e-commerce expansion. Near-term visibility on margins and core organic growth remains poor, so upside depends on tariff resolution, margin stabilization and clearer deleveraging progress.

Key Decisions for Investors

• Reduce or avoid initiating new long positions until the company demonstrates stabilization in gross margins and visible progress on tariff exposure or production re‑sourcing,
• Monitor three specific triggers for reassessment: (1) sequential improvement in adjusted EBITDA and cash‑flow conversion, (2) management commentary that tariffs are easing or being offset by pricing/operational changes, and (3) cessation of material EPS downgrades by analysts,
• If maintaining positions, consider downside protection (e.g., put options or collars) given elevated leverage from the Rhode acquisition and short‑term earnings risk,
• Only consider adding exposure on clear evidence of deleveraging (meaningful debt reduction or cash flow improvement) coupled with renewed organic growth in core U.S. and European channels